The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Who's watching?
It's very quiet on here, are people just sitting waiting for news to then have something to chat about? The 6 monthly return wasn't quite the RNS we were hoping for today, maybe we'll get something after hours regarding the Barrick deal - fingers crossed!
@JHFH given HEMO's setup and what people have said about Dr Vlad's ambitions I think it's highly likely he'd rather a takeover whereby he gets a position in at the deep end to watch everything come to fruition, rather than simply licence out - imo anyway.
The potential market might be $9B annually but if a takeover happens anytime soon I can't see that being a realistic offer tbh, but I guess it depends on the exact results. Globalco et al would want a significant discount to take on any risk. But hey, with a current mcap of £24M I'll take a $1-$2B offer any day!
@JHFH many thanks, I appreciate you taking the time to walk me through the logic of that.
So Eli announced on 16 Jan they'd be making acquisitions roughly every quarter - obvs this was before Covid properly struck so that could impact their bottom line, but likely in their specialisms more positively rather than negatively - and that was a week after they had acquired Demira.
Assuming that's their first quarter gone (jan - mar, depending on FYs like you say) It's now second quarter april to june which means they're likely due an announcement, I doubt this would be HEMO as it's not sufficient time since the placing to make real headway and we still await the completion of the globalco CDX development. However, if Eli announce another acquisition then that gives a rough timeline for their next one.
It does seem probably that it's Eli and I've read the speculation on this board before. Just a waiting game as ever with that one I guess - whether a takeover comes from it or not, the globalco news and hopefully the successful development completion should be exciting for the market and HEMO moving forward.
Is the thinking that the placing a month ago was to get our ducks lined up ready for a takeover... i.e to make us more attractive..? Surely globalco would’ve stumped up the cash if needed for the full placing having worked with us for a while now to take some of the company on the cheap?
I seem to remember someone mentioning previously that Kanav Kahol (Pinktech design / Divoc link) was just in AI/tech. Well he's most definitely a health innovator, pretty incredible https://www.linkedin.com/posts/kanav-kahol-715450112_innovation-covid19-tech4good-activity-6678536493214003200-PV_0
"My Nephew was born last Tuesday in the middle of COVID epidemic. He was born healthy with blood group A+, mother was A-ve. He was discharged the next day but soon he started turning yellow showing symptoms of newborn jaundice. In usual cases admitted to the hospital for phototherapy. However hospitals are now very resistant to taking in patients. So we were told to simply go home but given blood groups we knew phototherapy was needed. So I did my research and built a phototherapy unit for him at home. i found out that the phototherapy systems use 450nm lights which is also the light used in aquariums to light them up. I went to daryaganj found 6 of these lights for Rs 250 each and then using materials available at home developed a home phototherapy unit. Using light meter I checked that the light was the right luminance levels. After 48 hours in this home grown innovation for my own blood, we managed to get his bilirubin levels down to 3.4 which is normal. It is nerve wracking to develop something that your own family has to use but we were confident of this systems success. We will be releasing the design of this in opensource so people in rural India can benefit from this and happy to enable any clinic or hospital build such systems."
But surely they would've had to have accumulated that many in free float? Given the continuous walk down but still with buys often outstripping sells I don't understand how they could've done it. Is there a way?
@tradeinvestor I think you only need to have listened to DB's presentation on Friday - he didn't come across too bullish in the interviews the other week but you could tell he definitely had confidence on Friday. You're always going to get people on here with differing opinions and nutters both +ve and -ve, so best advice is probably to just ignore most of the things that are posted and listen to DB and read the RNSs instead
@mojo right here with you mate - topping up on the way up and topping up on the way down lol
Hindsight is both a benefit and a nightmare. And how has it already been 6 weeks since that fateful day...? Ah well, I think the next 6 weeks will prove to be worth it, even if we could've made more selling then and buying back in now - always going to be the way
@tradeinvester It was £1.5M/week and if they can achieve that it would be great. I still think they will have been manufacturing the 6M tests they had the financing for and pretty much be ready to go with those if a bulk order comes in but who knows.
Like @marve said earlier, sales don't need to be huge at this sp to make a big gain and tbh they aren't all going to land at once. I think what the market needs is confirmation that GDR can actually achieve sales and of decent quantity/potential for months ahead and then people will start piling in
@marve I agree, at this price the sales don't need to be significant to support it but obviously your example is a one-off and we'd need to know there was regular revenue to sustain the mcap - I think with HCV and AIHL on the horizon this is inevitable and with about ~£40M annually from AIHL once this kicks in we should be more like £200M mcap just with that.
Ideally the sales RNS will outline the interested markets and demonstrate that Covid revenue is going to come from multiple sources and not just one order or country.